Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?

Abstract

Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened. In our study, we aimed to evaluate patients with HFpEF who were followed up in our internal medicine clinic. Methods: Our retrospective and cross-sectional study included 348 patients with HFpEF. Patients were evaluated according to laboratory, demographic, clinical, electrocardiographic and ultrasonographic findings. Results: Of the patients, 37.95% had diabetes mellitus, 23.3% had chronic kidney disease, 70.1% had hypertension and 59.2% had metabolic dysfunction-associated steatotic liver disease. The mean NT-proBNP level was 360.7 ± 13.7. Conclusion: We recommend that HFpEF, which is associated with increased cardiovascular mortality and morbidity in patients with CRMD, should be screened clinically and with NT-proBNP and evaluated with transthoracic echocardiography if necessary.

Keywords

• CRMD
• Diabetes mellitus
• HFpEF
• Hypertension
• MASLD

References

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi:10.1093/eurheartj/ehab670.]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart association. Circulation. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
3. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, et al. Research priorities for heart failure with preserved ejection fraction: National heart, lung, and blood institute working group summary. Circulation. 2020;141(12):1001-1026. doi:10.1161/CIRCULATIONAHA.119.041886
4. Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, et al. Quality of life in heart failure with preserved ejection fraction: Importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020;22(6):1009-1018. doi:10.1002/ejhf.1788
5. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. doi:10.1016/j.jacc.2013.02.092
6. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750-1757. doi:10.1093/eurheartj/ehr254
7. Ostrominski JW, Claggett BL, Miao ZM, McCausland FR, Anand IS, Desai AS, et al. Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: A trial-level analysis. J Am Coll Cardiol. 2024;84(2):223-228. doi:10.1016/j.jacc.2024.05.005
8. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858

9. Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145-155. doi:10.1002/clc.23321
10. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of care in diabetes-2024. Diabetes care. 2024;47(Suppl 1):S179–S218. doi:10.2337/dc24-S010
11. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of hepatology. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031
12. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701-709. doi:10.1016/j.jchf.2018.05.018
13. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-259. doi:10.1056/NEJMoa052256
14. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology [published correction appears in Cardiovasc Res. 2023 Jun 13;119(6):1453. doi: 10.1093/cvr/cvad026.]. Cardiovasc Res. 2023;118(17):3272-3287. doi:10.1093/cvr/cvac013
15. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87(4):413-419. doi:10.1016/s0002-9149(00)01393-x
16. Potter EL, Hopper I, Sen J, Salim A, Marwick TH. Impact of socioeconomic status on incident heart failure and left ventricular dysfunction: Systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2019;5(2):169-179. doi:10.1093/ehjqcco/qcy047
17. Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghiade M, Butler J. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;69(5):556-569. doi:10.1016/j.jacc.2016.10.078
18. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. doi:10.1038/nrcardio.2014.83
19. Sengul S, Akpolat T, Erdem Y, et al. Changes in hypertension prevalence, awareness, treatment, and control rates in Turkey from 2003 to 2012. J Hypertens. 2016;34(6):1208-1217. doi:10.1097/HJH.0000000000000901
20. Jackson AM, Rørth R, Liu J, Kristensen SL, Anand IS, Claggett BL, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24(3):497-509. doi:10.1002/ejhf.2403
21. Abudureyimu M, Luo X, Wang X, Sowers JR, Wang W, Ge J, et al. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: From pathophysiology to therapeutics. J Mol Cell Biol. 2022;14(5):mjac028. doi:10.1093/jmcb/mjac028
22. Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou-Ezzedine OF, Fudim M, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: A RELAX trial ancillary study. Mayo Clin Proc. 2019;94(7):1199-1209. doi:10.1016/j.mayocp.2018.11.037
23. Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606-1614. doi:10.1002/ejhf.821
24. Lian LY, Huang CX, Chen QF, Zhou XD. Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution. World J Cardiol. 2025;17(2):103845. doi:10.4330/wjc.v17.i2.103845
25. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781. doi:10.1016/S0140-6736(03)14285-7